Abstract

Aging is a natural process that is characterized by chronic, low-grade inflammation, which represents the primary risk factor in the pathogenesis of a variety of diseases, i.e. aging-related diseases. RIP kinases, in particular RIPK1 and RIPK3, have emerged as master regulators of proinflammatory responses that act either by causing apoptosis and necroptosis or by directly regulating intracellular inflammatory signaling. While, RIPK1/3 and necroptosis are intimately linked to multiple human diseases, the relationship among RIPK1/3, necroptosis, and aging remains unclear. In this review, we discuss current evidence arguing for the involvement of RIPK1/3 and necroptosis in the progression of aging. In addition, we provide updated information and knowledge on the role of RIPK1/3 and necroptosis in aging-related diseases. Leveraging these new mechanistic insights in aging, we postulate how our improved understanding of RIPK1/3 and necroptosis in aging may support the development of therapeutics targeting RIPK1/3 and necroptosis for the modulation of aging and treatment of aging-related diseases.

Details

Title
RIP kinases and necroptosis in aging and aging-related diseases
Author
Yang, Yuanxin 1 ; Li, Xingyan 1 ; Zhang, Tao 2 ; Xu, Daichao 1 

 Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences , Shanghai 201210 , China 
 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA 02215 , United States 
Pages
2-20
Publication year
2022
Publication date
Aug 2022
Publisher
Oxford University Press
e-ISSN
27551733
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3191347339
Copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.